Reports Q3 revenue $184.9M, consensus $. “Our recent fiscal third quarter was a record quarter for Bio-Techne. Just a few years ago we were envisioning a time with results we are now reporting,” said Chuck Kummeth, President and CEO of Bio-Techne. “Our businesses, led by our antibody portfolio and Simple Western instruments, all performed well. Our Genomics division also recovered, just as we said it would, with strong double-digit growth in the quarter. Our results all year have shown that our acquisitions are integrating well, and providing increased organic growth now on top of an ever improving core reagent business.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.